Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. colorectal carcinoma
Show results for
Products

Companies

News
Articles

Refine by
Date

  • Older

Colorectal Carcinoma Articles & Analysis

4 news found

Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences

Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences

Data from this presentation demonstrate that Senti Bio’s CAR-NK cell manufacturing process will likely support translation to GMP clinical manufacturing in support of multiple allogeneic CAR-NK cell therapy products across the Company’s pipeline, including planned clinical development of SENTI-202 for acute myeloid leukemia and SENTI-301 for hepatocellular carcinoma. ...

BySenti Biosciences


Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...

BySenti Biosciences


Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Our synthetic biology platform utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid oncology indications, including acute myeloid leukemia, hepatocellular carcinoma, and colorectal cancer. We have also demonstrated the breadth of our Gene ...

BySenti Biosciences


Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas.1 Clovis will conduct global clinical trials and has obtained U.S. and global rights, excluding Europe (inclusive of Russia, Turkey and Israel), where 3BP retains rights. ...

By3B Pharmaceuticals GmbH

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT